JP2009534397A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009534397A5 JP2009534397A5 JP2009506662A JP2009506662A JP2009534397A5 JP 2009534397 A5 JP2009534397 A5 JP 2009534397A5 JP 2009506662 A JP2009506662 A JP 2009506662A JP 2009506662 A JP2009506662 A JP 2009506662A JP 2009534397 A5 JP2009534397 A5 JP 2009534397A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pyrimidinediamine
- fluoro
- neoplasm
- oxazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/407,233 US8227455B2 (en) | 2005-04-18 | 2006-04-18 | Methods of treating cell proliferative disorders |
| US11/407,233 | 2006-04-18 | ||
| PCT/US2007/064511 WO2007124221A1 (en) | 2006-04-18 | 2007-03-21 | Methods of treating cell proliferative disorders by using pyrimidinediamine compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009534397A JP2009534397A (ja) | 2009-09-24 |
| JP2009534397A5 true JP2009534397A5 (https=) | 2011-05-12 |
| JP5204761B2 JP5204761B2 (ja) | 2013-06-05 |
Family
ID=38477280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506662A Active JP5204761B2 (ja) | 2006-04-18 | 2007-03-21 | ピリミジンジアミン化合物を使用することによる細胞増殖性障害を処置する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8227455B2 (https=) |
| EP (1) | EP2010181B1 (https=) |
| JP (1) | JP5204761B2 (https=) |
| AT (1) | ATE499102T1 (https=) |
| CA (1) | CA2649549C (https=) |
| DE (1) | DE602007012677D1 (https=) |
| DK (1) | DK2010181T3 (https=) |
| ES (1) | ES2364657T3 (https=) |
| SI (1) | SI2010181T1 (https=) |
| WO (1) | WO2007124221A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005013996A2 (en) | 2003-08-07 | 2005-02-17 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
| US8227455B2 (en) * | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| WO2008061201A1 (en) * | 2006-11-15 | 2008-05-22 | Rigel Pharmaceuticals, Inc. | Methods for treating renal tumors using 2,4-pyrimidinediamine drug and prodrug compounds |
| US20090012045A1 (en) * | 2007-06-26 | 2009-01-08 | Rigel Pharmaceuticals, Inc. | Methods of Treating Cell Proliferative Disorders |
| WO2009029682A1 (en) * | 2007-08-28 | 2009-03-05 | Rigel Pharmaceuticals, Inc. | Combination therapy with syk kinase inhibitor |
| MY169761A (en) * | 2007-11-07 | 2019-05-15 | Rigel Pharmaceuticals Inc | Wet granulation using a water sequestering agent |
| AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| BRPI0910509B8 (pt) | 2008-07-10 | 2021-05-25 | Toray Industries | uso do anticorpo, anticorpo e composição farmacêutica |
| ES2555982T3 (es) | 2009-01-15 | 2016-01-12 | Rigel Pharmaceuticals, Inc. | Inhibidores de la proteína quinasa C y usos de los mismos |
| ES2524127T3 (es) | 2009-11-20 | 2014-12-04 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidinodiamina y sus profármacos y sus usos |
| CA2792278C (en) | 2010-04-13 | 2019-05-14 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses |
| US8927547B2 (en) | 2010-05-21 | 2015-01-06 | Noviga Research Ab | Pyrimidine derivatives |
| WO2012002577A1 (ja) | 2010-06-30 | 2012-01-05 | 富士フイルム株式会社 | 新規なニコチンアミド誘導体またはその塩 |
| DK2688883T3 (en) | 2011-03-24 | 2016-09-05 | Noviga Res Ab | pyrimidine |
| WO2012167423A1 (en) | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
| PT2736487T (pt) | 2011-07-28 | 2019-02-13 | Rigel Pharmaceuticals Inc | Novas formulações de (trimetoxifenilamino) pirimidinilo |
| DK2799431T3 (en) | 2011-12-28 | 2018-03-26 | Fujifilm Corp | Hitherto unknown nicotinamide derivatives or salts thereof |
| UY34807A (es) | 2012-05-16 | 2013-12-31 | Novartis Ag | Derivados monocíclicos de heteroarilcicloalquil- diamina |
| WO2013189241A1 (zh) * | 2012-06-20 | 2013-12-27 | 上海恒瑞医药有限公司 | 嘧啶二胺类衍生物、其制备方法及其在医药上的应用 |
| CN103804382A (zh) * | 2012-11-05 | 2014-05-21 | 韩文毅 | 一类治疗湿疹的化合物及其用途 |
| CN103102412B (zh) * | 2013-01-29 | 2014-03-26 | 陈仁杰 | 人源抗鼻咽癌LMP2A胞外区抗体Fab及其应用 |
| WO2016118014A2 (en) * | 2015-01-23 | 2016-07-28 | Erasmus University Medical Center Rotterdam | Anti-senescence compounds and uses thereof |
| JP6833816B2 (ja) * | 2015-08-12 | 2021-02-24 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ） |
| PL3371171T3 (pl) * | 2015-11-02 | 2024-03-25 | Blueprint Medicines Corporation | Inhibitory RET |
| RU2621187C1 (ru) * | 2016-05-13 | 2017-06-01 | Общество с ограниченной ответственностью "Молекулярные Технологии" | Новая кристаллическая солевая форма 2,2-диметил-6-((4-((3,4,5-триметоксифенил)амино)-1,3,5-триазин-2-ил)амино)-2н-пиридо[3,2-в][1,4]оксазин-3(4н)-она для медицинского применения |
| TW201822764A (zh) | 2016-09-14 | 2018-07-01 | 美商基利科學股份有限公司 | Syk抑制劑 |
| US10111882B2 (en) | 2016-09-14 | 2018-10-30 | Gilead Sciences, Inc. | SYK inhibitors |
| WO2018195471A1 (en) | 2017-04-21 | 2018-10-25 | Gilead Sciences, Inc. | Syk inhibitors in combination with hypomethylating agents |
| SI3773589T1 (sl) | 2018-04-03 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitor RET za uporabo pri zdravljenju raka, ki ima RET spremembo |
| JP2023527412A (ja) | 2020-05-29 | 2023-06-28 | ブループリント メディシンズ コーポレイション | プラルセチニブの固体形態 |
| WO2023182460A1 (ja) * | 2022-03-24 | 2023-09-28 | 学校法人 聖マリアンナ医科大学 | 慢性活動性Ｅｐｓｔｅｉｎ－Ｂａｒｒウイルス感染症（ＣＡＥＢＶ）の検出方法 |
| WO2024037910A1 (en) * | 2022-08-17 | 2024-02-22 | Institut National de la Santé et de la Recherche Médicale | Syk inhibitors for use in the treatment of cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| KR20010033811A (ko) * | 1997-12-31 | 2001-04-25 | 토마스 안 빅토리아 | 2차 및 3차 아민을 함유하는 약제의 물에 용해가능한프로드럭 및 그것의 제조방법 |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| EP1343782B1 (en) | 2000-12-21 | 2009-05-06 | SmithKline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2003026664A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
| WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
| AU2002367172A1 (en) | 2001-12-21 | 2003-07-15 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| HRP20040853A2 (en) * | 2002-03-20 | 2004-12-31 | Bristol Myers Squibb Co | Phosphate prodrugs of fluorooxindoles |
| ES2445208T3 (es) | 2002-07-29 | 2014-02-28 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias |
| AU2003260344A1 (en) | 2002-08-02 | 2004-02-25 | Vanetta S.P.A. | Redox process particularly for the production of menadione and use of polyoxometalates |
| US20040235834A1 (en) | 2003-03-25 | 2004-11-25 | Farmer Luc J. | Thiazoles useful as inhibitors of protein kinases |
| BRPI0413018B8 (pt) * | 2003-07-30 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, e, uso de um composto |
| WO2005013996A2 (en) | 2003-08-07 | 2005-02-17 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
| WO2005027848A2 (en) | 2003-09-19 | 2005-03-31 | Barnes-Jewish Hospital | Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators |
| US20050192314A1 (en) * | 2003-11-13 | 2005-09-01 | Ambit Biosciences Corporation | Urea derivatives as C-kit modulators |
| EP1814878B1 (en) | 2004-11-24 | 2012-01-04 | Rigel Pharmaceuticals, Inc. | Spiro-2, 4-pyrimidinediamine compounds and their uses |
| DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| US8227455B2 (en) | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| WO2008061201A1 (en) | 2006-11-15 | 2008-05-22 | Rigel Pharmaceuticals, Inc. | Methods for treating renal tumors using 2,4-pyrimidinediamine drug and prodrug compounds |
-
2006
- 2006-04-18 US US11/407,233 patent/US8227455B2/en active Active
-
2007
- 2007-03-21 SI SI200730591T patent/SI2010181T1/sl unknown
- 2007-03-21 JP JP2009506662A patent/JP5204761B2/ja active Active
- 2007-03-21 ES ES07759007T patent/ES2364657T3/es active Active
- 2007-03-21 AT AT07759007T patent/ATE499102T1/de not_active IP Right Cessation
- 2007-03-21 EP EP07759007A patent/EP2010181B1/en active Active
- 2007-03-21 WO PCT/US2007/064511 patent/WO2007124221A1/en not_active Ceased
- 2007-03-21 CA CA2649549A patent/CA2649549C/en active Active
- 2007-03-21 DE DE602007012677T patent/DE602007012677D1/de active Active
- 2007-03-21 DK DK07759007.3T patent/DK2010181T3/da active
-
2012
- 2012-06-04 US US13/487,979 patent/US8481521B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009534397A5 (https=) | ||
| AU2011302344B2 (en) | HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients | |
| JP2023542066A (ja) | 抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ | |
| US20220110940A1 (en) | Combinations for the treatment of neoplasms using quiescent cell targeting with egfr inhibitors | |
| US12083136B2 (en) | Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof | |
| JPWO2016204193A1 (ja) | 抗がん剤 | |
| JP2014520808A (ja) | Ｈｓｐ９０阻害化合物を用いた癌の治療 | |
| CN111558044A (zh) | 一种包含舒尼替尼的药物组合物及其制剂和应用 | |
| JP6558757B2 (ja) | 抗腫瘍剤 | |
| JP6063472B2 (ja) | 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法 | |
| WO2017159877A1 (en) | Use of eribulin and 3-quinuclidinone derivatives in the treatment of cancer | |
| US11491168B2 (en) | Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof | |
| Allen et al. | The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer | |
| BR112021015908A2 (pt) | Composição antitumoral | |
| JP2013523867A5 (https=) | ||
| JP7493503B2 (ja) | Ｍｃｌ－１阻害剤とミドスタウリンとの組み合わせ、その使用及び医薬組成物 | |
| JP6886278B2 (ja) | 抗癌剤 | |
| Yi et al. | Recent advances in understanding and managing T-cell lymphoma | |
| JP5802658B2 (ja) | 人および動物の腫瘍性疾患の治療、抑制あるいは予防用医薬組成物、および医薬組成物の使用 | |
| Zhang et al. | Receptor tyrosine kinases in carcinogenesis (Review) Retraction in/10.3892/ol. 2020.12062 | |
| TW201008945A (en) | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents | |
| JP5987175B2 (ja) | 乳癌，胃癌及び卵巣癌等に対する制癌剤 | |
| JP2020063209A (ja) | 細胞周期停止剤および抗腫瘍剤 | |
| Hedman et al. | 279 NC-001 induces tumor growth discontinuation and necrosis in a xenograft renal cancer rat model | |
| Hanauske et al. | 64 POSTER Phase I study of pemetrexed followed by daily enzastaurin in patients with advanced or metastatic cancer |